Stock of the Day

March 6, 2023

Globus Medical (GMED)

$81.44
-$1.53 (-1.8%)
Market Cap: $11.14B

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Today's Trend

Globus Medical, Inc. (NYSE: GMED) shares have increased as analysts signal improving earnings prospects and continued investor interest in the medical-device company. The stock remains below its 52-week high, while its latest reported quarter showed earnings and revenue ahead of expectations.

  • Broad upward revisions to earnings estimates: Zacks Research raised its FY2026 EPS forecast to $4.97 from $4.74 and its FY2027 forecast to $5.06 from $4.75. It also increased estimates for several upcoming quarters, including Q3 2026, Q1 and Q2 2027, Q3 2027, and Q1 and Q2 2028. The revisions suggest stronger expected profitability and support the stock’s bullish outlook. Zacks maintains a “Strong-Buy” rating. MarketBeat Globus Medical estimates report
  • Analysts see substantial upside: The average Wall Street price target implies approximately 25% potential appreciation for GMED. Although price targets are not always reliable, the article notes that analysts’ agreement in raising earnings estimates is a more constructive signal for the shares. Wall Street analysts believe Globus Medical could rally
  • Recent operating momentum provides support: Globus Medical’s latest quarterly results exceeded analyst expectations, with EPS of $1.34 versus a $1.10 consensus estimate and revenue of $789.6 million versus $782.9 million expected. Revenue rose 5.9% year over year, reinforcing the case for the higher forward estimates.
  • Favorable investment-style coverage: Zacks highlighted GMED as a top-ranked momentum stock and compared it with Integer for value investors. These articles may improve visibility but do not represent new company fundamentals or a formal rating change. Globus Medical is a top-ranked momentum stock
← Previous Stock of the DayNext Stock of the Day →

Recent News